Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173913 | 0.74 | — | — | |
| SCHEMBL28202303 | 0.64 | ALDH1A1 (0.31) | — | |
| SCHEMBL30816546 | 0.64 | — | — | |
| SCHEMBL698926 | 0.62 | CDC25B (0.31) | CDC25B | |
| SCHEMBL16783401 | 0.59 | — | — | |
| SCHEMBL16521057 | 0.58 | — | — | |
| SCHEMBL31061724 | 0.57 | — | — | |
| SCHEMBL30525275 | 0.57 | — | — | |
| SCHEMBL725529 | 0.57 | — | — | |
| SCHEMBL30525274 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365574-B2 | Soluble guanylate cyclase activators | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | claimed |
| EP-2373317-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Merck Sharp & Dohme Corp. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | claimed |
| WO-2010065275-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. (US) | 2010-06-10 | — | — | WO | claimed |
| WO-2025235367-A1 | AZAINDOLINONE COMPOUNDS AS KCA3.1 POTASSIUM CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-118406056-A | Aza-2-indolone derivative and synthesis method thereof | 渭南瑞联制药有限责任公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-117720532-A | Pyrrolopyrimidine derivatives as RSK inhibitors and use thereof | 华东师范大学 | 2024-03-19 | — | — | CN | disclosed |
| EP-3458066-B1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3790546-A1 | THE USE OF NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | Bayer Aktiengesellschaft (DE) | 2021-03-17 | — | — | EP | disclosed |
| WO-2019215317-A1 | THE USE OF NON-STEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS ALONE OR IN COMBINATION FOR THE TREATMENT OF MUSCULAR OR NEUROMUSCULAR DISEASES | BAYER AKTIENGESELLSCHAFT (DE) | 2019-11-14 | — | — | WO | disclosed |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-24 | — | — | US | disclosed |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-17 | — | — | US | disclosed |
| WO-2011161099-A1 | USE OF STIMULATORS AND ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE FOR TREATING SICKLE-CELL ANEMIA AND CONSERVING BLOOD SUBSTITUTES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-29 | — | — | WO | disclosed |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME CORP. | 2011-09-08 | — | — | US | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-26 | — | — | US | disclosed |
| US-7138402-B2 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION | 2005-05-19 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107343-A1 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | CDC25B 118/4885 |
| US-20170240566-A1 | AMINO-SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, TYMS, DPYD | CDC25B 977/4885 |
| US-20170233413-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND USE THEREOF | TYMP, DPYD, TYMS | CDC25B 942/4885 |
| US-20070173483-A1 | Pyrrolopyrimidines and Related Analogs as HSP90-Inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | CDC25B 118/4885 |
| US-20110218202-A1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | PDE2A, GUCY1A2, PDE3A | CDC25B 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.